Abstracts tagged "lupus-like disease"

Abstract Number: PP11 • ACR Convergence 2020
“Knitting a Community of Hope”- Supporting, Empowering and Educating Those Living with Lupus, and Overlapping Conditions and Their Loved Ones via in Person and Virtual Support Groups That Include Art Therapy, and Wellness Techniques Is Key; Mental Health Is as Important as Physical Health
Juana Mata¹ and Ma. Estela Mata-Carcamo², ¹Looms for Lupus, La Puente, CA, ²Looms for Lupus, Baldwin Park, CA

Background/Purpose: Juana was Diagnosed with Rheumatoid Arthritis in April 2009. In May 2009 she ended up in the hospital with a variety of symptoms and…
Abstract Number: PP12 • ACR Convergence 2020
COVID-19, Racism, and Gender Discrimination: The Function of Stress in Widening the Gap in Health Disparities
Carly Harrison¹ and Christele Felix², ¹LupusChat, Richmond, VA, ²LupusChat, Rosedale, NY
Background/Purpose: Populations experiencing rheumatic diseases are often at higher risk of increased levels of stress. This may result in disease complications and can potentially lead…
Abstract Number: 0436 • ACR Convergence 2020
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, Sanjyot Sangodkar², Kathleen Arntsen³, Sang-Cheol Bae⁴, Lauren Bloch², Ian Bruce⁵, Erin Connolly-Strong⁶, Karen Costenbader⁷, Thomas Dörner⁸, Sydney Evans⁹, Timothy Franson², Kenneth Getz¹⁰, Amy Kao¹¹, Kenneth Kalunian¹², Bradley Dickerson¹³, Susan Manzi¹⁴, Eric Morand¹⁵, Yaritza Peña¹⁰, Sandra Raymond¹⁶, Brad Rovin¹⁷, Laura Schanberg¹⁸, Joan Von Feldt¹⁹, Victoria Werth²⁰, Angel Williams²¹, David Zook² and Leslie Hanrahan¹⁶, ¹Lupus Foundation of America, DC, WA, ²Faegre Drinker Consulting, Washington, DC, ³Lupus and Allied Diseases Association, Inc., Verona, NY, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Mallinckrodt, Austin, TX, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸DRFZ and Charité University Hospitals, Berlin, Germany, ⁹Lupus Patient Representative, Riverdale, MD, ¹⁰Tufts Center for the Study of Drug Development, Boston, MA, ¹¹EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹²University of California San Diego, La Jolla, CA, ¹³Aurinia Pharmaceuticals, Fort Washington, PA, ¹⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹⁶Lupus Foundation of America, Washington, DC, ¹⁷The Ohio State University, Columbus, ¹⁸Duke University Medical Center, Durham, NC, ¹⁹GlaxoSmithKline, WILMINGTON, DE, ²⁰University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²¹Lupus Patient Representative, Richmond, VA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritize and address top barriers in lupus impacting…
Abstract Number: 0845 • ACR Convergence 2020
Hematopoietic Specific Deficiency of Rho Kinase Attenuates Neutrophil NETosis and UVB-induced Skin Inflammation
Minghui Li¹, Xing Lyu¹, Yubin Li², James Liao³, Victoria Werth⁴ and Ming-Lin Liu¹, ¹University of Pennsylvania, philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Chicago, Chicago, ⁴University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Neutrophils are the most abundant leukocytes and the first to be recruited to the site of photodamage after ultraviolet B (UVB) exposure. We have…
Abstract Number: 1449 • ACR Convergence 2020
Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
Alejandra Maria Patiño-Trives¹, Alejandro Ibáñez-Costa², Carlos Pérez-Sánchez¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Desirée Ruiz-Vilchez⁴, Pedro Segui⁵, Mario Espinosa⁵, Nuria Barbarroja¹, Eduardo Collantes⁴, Justo P. Castaño⁵, Raul M Luque⁵, María de los ángeles Aguirre-Zamorano⁵ and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba
Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
Abstract Number: 74 • 2019 ACR/ARP Annual Meeting
LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies
Yundi Tang¹, Yuxuan Wang ¹, Yundong Zou ¹, Mengru Liu ¹, Yan Du ¹ and Jianping Guo ¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble member of LILR family. We previously reported that LILRA3 is a novel genetic risk for multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].